ACACIA RESEARCH CORPORATION

(ACTG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Exclusive-Macellum asks Kohl's for board seat, public commitment to explore sale

01/25/2022 | 06:36pm EDT
A Kohl’s department store in New York

BOSTON(Reuters) - Activist hedge fund Macellum Advisors, which wants Kohl's Corp to consider putting itself up for sale, is now pressing the U.S. retailer for at least one board seat and a public statement that the company is reviewing strategic alternatives, according to a letter reviewed by Reuters.

Macellum, which owns roughly 5% of Kohl's stock, sent the letter hours after Acacia Research Corp, backed by activist investor Starboard Value, on Monday confirmed an offer to buy the company for $64 a share, valuing Kohl's at roughly $9 billion.

In addition to Acacia's bid, Sycamore Partners is also preparing an all-cash offer for Kohl's at $65 per share, sources said on Sunday.

Kohl's shares surged 36% on Monday to close at $63.71.

"The best risk-adjusted path forward for shareholders right now is a credible and open process to evaluate a full sale of the company at an attractive premium," Macellum's managing partner Jonathan Duskin wrote. "Investors want an organized sales process."

He wants Kohl's to provide at least one unconditional board seat for a Macellum representative and to have that person lead a new committee that will oversee the review process, the letter said.

"We do not have faith in the current board to run this process on its own, nor do we believe the Board is capable of objectively evaluating possible bids," Duskin wrote.

A representative for Kohl's declined to address the Macellum letter directly on Tuesday and referred back to a statement from Monday which said the company will not make further public comment on expressions of interest unless "it is in the best interests of the shareholders."

Kohl's is exploring its options, including a possible sale, with advice from investment bank Goldman Sachs, two sources familiar with the matter said.

The people with knowledge of the matter declined to be identified because they were not permitted to discuss it publicly.

Pressure has been building on Kohl's since last week when Macellum said it planned to nominate directors to the board and wanted the company to consider a sale, and when Reuters reported that Acacia Research was preparing a bid for the company.

Duskin is ratcheting up that pressure less than a year after he and others reached a settlement that saw the company add three new directors.

He said in the letter reviewed by Reuters that he may take legal action or run another proxy contest if Kohl's board "chills" a sale process.

(Reporting by Svea Herbst-Bayliss; Editing by Kenneth Maxwell)

By Svea Herbst-Bayliss


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ACACIA RESEARCH CORPORATION -1.11% 4.47 Delayed Quote.-12.87%
DUSKIN CO., LTD. -1.59% 2728 Delayed Quote.-1.32%
KOHL'S CORPORATION 1.96% 48.44 Delayed Quote.-1.92%
All news about ACACIA RESEARCH CORPORATION
05/12ACACIA RESEARCH CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
AQ
05/12TRANSCRIPT : Acacia Research Corporation, Q1 2022 Earnings Call, May 12, 2022
CI
05/12Earnings Flash (ACTG) ACACIA RESEARCH CORPORATION Posts Q1 Revenue $13.5M
MT
05/12ACACIA RESEARCH : Q1 Earnings Snapshot
AQ
05/12Earnings Flash (ACTG) ACACIA RESEARCH CORPORATION Reports Q1 Revenue $13.5M
MT
05/12Acacia Research Corporation Reports Earnings Results for the First Quarter Ended March ..
CI
05/12Acacia Research Reports First Quarter 2022 Financial Results
BU
05/06Acacia Research to Release First Quarter 2022 Financial Results on May 12, 2022
BU
05/04Arix Bioscience Shareholder Acacia Research Lifts Stake To 21%
MT
05/04Acacia Research Reportedly Says It Doesn't Expect to Make Offer for Arix Bioscience, Bl..
MT
More news
Financials (USD)
Sales 2022 54,0 M - -
Net income 2022 -81,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,54x
Yield 2022 -
Capitalization 205 M 205 M -
Capi. / Sales 2022 3,79x
Capi. / Sales 2023 3,47x
Nbr of Employees 287
Free-Float 86,0%
Chart ACACIA RESEARCH CORPORATION
Duration : Period :
Acacia Research Corporation Technical Analysis Chart | ACTG | US0038813079 | MarketScreener
Technical analysis trends ACACIA RESEARCH CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 4,47 $
Average target price 8,00 $
Spread / Average Target 79,0%
EPS Revisions
Managers and Directors
Clifford Press President, Chief Executive Officer & Director
Richard J. Rosenstein Chief Financial Officer
Maureen E. O'Connell Chairman
Martin D. McNulty Chief Operating Officer, Head-M&A
Wesley Lawrence Golby Chief Investment Officer
Sector and Competitors
1st jan.Capi. (M$)
ACACIA RESEARCH CORPORATION-12.87%205
CINTAS CORPORATION-15.16%38 471
TELEPERFORMANCE SE-19.72%19 241
BUREAU VERITAS SA-9.56%12 432
EDENRED SE10.75%11 624
LG CORP.-7.29%10 248